ArticleBMC microbiology2026
Bicuculline reversal of aminoglycoside O-nucleotidyltransferase EanT-1-mediated kanamycin resistance.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundKanamycin, an aminoglycoside, is an effective broad-spectrum antimicrobial agent against bacterial infections. However, the clinical efficacy of aminoglycosides has been overshadowed by the emergence of resistance mechanisms involving enzyme-mediated covalent modifications. Aminoglycoside nucleotidyltransferases (ANTs) inactivate aminoglycosides via AMP group transfer. Elucidating their molecular mechanisms and identifying effective inhibitors are critical for combating antimicrobial resistance.
methodsExiguobacterium sp. PL221A was isolated from hospital sewage under selection with 16 mg/L aminoglycosides. Following genomic sequencing using the Oxford Nanopore and BGISEQ-500 platforms, the eanT-1 gene encoding an ANT was identified, cloned, and expressed in Escherichia coli DH5α. Minimum inhibitory concentrations (MICs) against kanamycin were determined. Protein-ligand interactions between Eant-1 and kanamycin, virtual mutations of EanT-1, and inhibitor screening were assessed using the MaXFlow platform. To evaluate the catalytic mechanism, eant-1 mutants were expressed in vitro and their kinetic parameters were characterized. The impact of bicuculline on MICs and time-kill curves was also evaluated.
resultsStrain PL221A exhibited notable resistance to neomycin, kanamycin, and gentamicin (all MICs > 128 mg/L). Heterologous expression indicated that EanT-1 confers kanamycin resistance. Mutation of residues D43A and D98A abrogated enzymatic activity, whereas alanine substitutions at R51 and T100 had no apparent effect. Bicuculline, an isoquinoline alkaloid compound, was identified as an effective EanT-1 inhibitor, showing stronger binding affinity (-8.72 kcal/mol) for EanT-1 than kanamycin (-7.51 kcal/mol) and an ability to occupy aspartate residues critical for electrophilic polarization. Its hydroxyl-free alkaloid scaffold may prevent adenylation, enabling competitive binding with kanamycin at the catalytic site and inactivating EanT-1. Additionally, the combination of kanamycin and bicuculline effectively inhibited the growth of eanT-1-expressing bacteria.
conclusionsThe ANT encoded by eanT-1 in Exiguobacterium sp. PL221A mediates resistance to kanamycin, which can be counteracted by the alkaloid bicuculline through inhibition of its catalytic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.